Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin - AstraZeneca

Next Previous
Drug Profile

Dapagliflozin - AstraZeneca

Alternative Names: Andatang; AZ-dapagliflozin; BMS-512148; BMS-dapagliflozin; BMS/AZ-Dapagliflozin; DAPA; Dapagliflozin-AstraZeneca; Dapagliflozin-propanediol; Farxiga; Forxiga; Oxra

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; AstraZeneca KK; Bayer; Bristol-Myers Squibb; Novo Nordisk Foundation; Ono Pharmaceutical; University Medical Center Groningen; Uppsala University
  • Class Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase III COVID 2019 infections; Heart failure; Myocardial infarction
  • Phase II Kidney disorders; Liver cirrhosis; Obesity; Prediabetic state

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for clinical-Phase-Unknown development in Heart-failure(In the elderly, Prevention) in Australia (PO, Tablet)
  • 19 Mar 2024 AstraZeneca plans a phase III trial in Chronic heart failure (Combination therapy) in USA, Argentina, Australia, Austria, Canada, Chile, China, Colombia, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Kores, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, Vietnam (NCT06307652)
  • 11 Nov 2023 Efficacy data from a phase III trial in Heart failure presented at the the American Heart Association Scientific Sessions 2023 (AHA-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top